Collegium Pharmaceutical, Inc. (COLL)
35.01
+0.21
(+0.60%)
USD |
NASDAQ |
Jun 11, 12:09
Collegium Pharmaceutical EPS Diluted (Quarterly) : 0.3992 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.3992 |
| December 31, 2025 | 0.4604 |
| September 30, 2025 | 0.8385 |
| June 30, 2025 | 0.3446 |
| March 31, 2025 | 0.0736 |
| December 31, 2024 | 0.3501 |
| September 30, 2024 | 0.2677 |
| June 30, 2024 | 0.5221 |
| March 31, 2024 | 0.7079 |
| December 31, 2023 | 0.82 |
| September 30, 2023 | 0.5297 |
| June 30, 2023 | 0.3427 |
| March 31, 2023 | -0.5078 |
| December 31, 2022 | -0.2144 |
| September 30, 2022 | 0.0132 |
| June 30, 2022 | -0.1527 |
| March 31, 2022 | -0.3881 |
| December 31, 2021 | -0.7336 |
| September 30, 2021 | 0.2219 |
| June 30, 2021 | 1.764 |
| March 31, 2021 | 0.4088 |
| December 31, 2020 | 0.1965 |
| September 30, 2020 | 0.3218 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.2296 |
| March 31, 2020 | 0.0128 |
| December 31, 2019 | -0.0655 |
| September 30, 2019 | -0.1825 |
| June 30, 2019 | -0.1411 |
| March 31, 2019 | -0.291 |
| December 31, 2018 | 0.2691 |
| September 30, 2018 | -0.4999 |
| June 30, 2018 | -0.40 |
| March 31, 2018 | -0.57 |
| December 31, 2017 | -0.54 |
| September 30, 2017 | -0.45 |
| June 30, 2017 | -0.72 |
| March 31, 2017 | -0.79 |
| December 31, 2016 | -1.017 |
| September 30, 2016 | -1.13 |
| June 30, 2016 | -1.047 |
| March 31, 2016 | -0.6767 |
| December 31, 2015 | -0.4633 |
| September 30, 2015 | -0.46 |
| June 30, 2015 | -0.45 |
| March 31, 2015 | -0.65 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Phibro Animal Health Corp. | 0.5854 |
| ANI Pharmaceuticals, Inc. | 1.276 |
| Corcept Therapeutics, Inc. | -0.2988 |
| Assertio Holdings, Inc. | -2.931 |
| Veru, Inc. | -0.1342 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 14.50M |
| Revenue (Quarterly) | 193.52M |
| Total Expenses (Quarterly) | 179.02M |
| Enterprise Value | 1.616B |
| Gross Profit Margin (Quarterly) | 60.59% |
| Profit Margin (Quarterly) | 7.49% |
| Earnings Yield | 5.83% |
| Operating Earnings Yield | 13.86% |
| Normalized Earnings Yield | 6.812 |